Two widely used drugs, allopurinol and indomethacin, and the vitamin riboflavin increased the response of mice to ionizing radiation. In mice a dose of 10.5 Gy of γ rays from a60 Co source resulted in a dose-dependent shortening of survival times after pretreatment with the three agents, applied at doses which were well tolerated alone. When the dose dependency of these drugs on the influence on survival was tested, two response patterns emerged. Indomethacin (25 mg/kg) shifted the survival curve to the left and reduced the LD50 from ∼6.5 Gy to ∼4.5 Gy. Allopurinol (100 mg/kg) diminished the survival rate to approximately 50% irrespective of the radiation dose (ranging from 0.75 to 6.0 Gy). A similar though less striking trend was seen with riboflavin (120 mg/kg), which reduced the survival rate to approximately 65% in the dose range from 3 to 6 Gy. Mortality in mice treated with allopurinol or riboflavin and irradiated with nonlethal exposures (from radiation alone) occurred within the first few days after irradiation, suggesting a different type of injury than is usually associated with radiation death. Although doses of the three drugs used clinically are clearly lower than those providing enhanced radioresponse in our experiments, subtle and nonovert injury caused by combined exposure to the drugs and radiation cannot be completely excluded.
Skip Nav Destination
Close
Article navigation
August 1994
Research Article|
August 01 1994
Allopurinol, Indomethacin and Riboflavin Enhance Radiation Lethality in Mice
Radiat Res (1994) 139 (2): 240–247.
Citation
G. L. Floersheim; Allopurinol, Indomethacin and Riboflavin Enhance Radiation Lethality in Mice. Radiat Res 1 August 1994; 139 (2): 240–247. doi: https://doi.org/10.2307/3578670
Download citation file:
Close
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Sign in via your Institution
Sign in via your InstitutionCiting articles via
Commonalities Between COVID-19 and Radiation Injury
Carmen I. Rios, David R. Cassatt, Brynn A. Hollingsworth, Merriline M. Satyamitra, Yeabsera S. Tadesse, Lanyn P. Taliaferro, Thomas A. Winters, Andrea L. DiCarlo
Low-Dose Radiation Therapy (LDRT) for COVID-19: Benefits or Risks?
Pataje G. Prasanna, Gayle E. Woloschak, Andrea L. DiCarlo, Jeffrey C. Buchsbaum, Dörthe Schaue, Arnab Chakravarti, Francis A. Cucinotta, Silvia C. Formenti, Chandan Guha, Dale J. Hu, Mohammad K. Khan, David G. Kirsch, Sunil Krishnan, Wolfgang W. Leitner, Brian Marples, William McBride, Minesh P. Mehta, Shahin Rafii, Elad Sharon, Julie M. Sullivan, Ralph R. Weichselbaum, Mansoor M. Ahmed, Bhadrasain Vikram, C. Norman Coleman, Kathryn D. Held
Germicidal Efficacy and Mammalian Skin Safety of 222-nm UV Light
Manuela Buonanno, Brian Ponnaiya, David Welch, Milda Stanislauskas, Gerhard Randers-Pehrson, Lubomir Smilenov, Franklin D. Lowy, David M. Owens, David J. Brenner